Key Highlights

● Each ABVX ADS represents one ordinary share with a nominal value of EUR 0.01.

● Citibank, N.A. acts as depositary, under a deposit agreement governed by New York law.

● Seven obefazimod abstracts will be presented at UEG Week from 17 to 20 October 2026.

● Obefazimod is in Phase 3 development for moderately to severely active ulcerative colitis.

The American Depositary Shares (ADSs) of Abivax SA (NASDAQ:ABVX) trade on the Nasdaq Global Market. According to the company's description of securities filed with its annual report on Form 20-F for the year ended 31 December 2025, each ADS represents one ordinary share with a nominal value of EUR 0.01. The ordinary shares are registered on Nasdaq only in connection with the ADS programme and do not trade there. A press release from the company also lists a separate Euronext Paris line for the ordinary shares, which is a different instrument from the ADS.

Citibank, N.A. acts as depositary, with Citibank Europe plc in Dublin as custodian. The deposit agreement is governed by New York law, whilst the obligations of Abivax to its ordinary shareholders remain governed by French law. The registration statement on Form F-6 carries the number 333-274845.

What ADS holders do and do not hold

ADS holders have a beneficial interest in the deposited shares but are not treated as shareholders in their own right. They may exercise shareholder rights only through the depositary and only to the extent the deposit agreement allows. To obtain direct rights, a holder would need to cancel the ADSs and become a registered shareholder.

Cash distributions are converted into US dollars where practicable and paid net of fees, taxes and charges. Share dividends are delivered as additional ADSs, or the ratio is adjusted. The company had 78,536,412 ordinary shares outstanding at 31 December 2025, which is the figure for the underlying shares rather than a count of ADSs.

The latest disclosure

On 30 September 2026 the company announced that seven abstracts on its lead candidate, obefazimod, will be presented at United European Gastroenterology Week, held in Barcelona from 17 to 20 October 2026. Four are oral presentations and three are posters. Obefazimod is being developed for moderately to severely active ulcerative colitis and is in Phase 3 development.

The schedule includes an e-poster on 17 October on tumour burden in a murine model of colitis-associated cancer, presented by Professor Silvio Danese. On 18 October two moderated posters cover three-year interim Phase 2 open-label data after dose reduction to 25 mg, and a pooled analysis linking bowel urgency and nocturnal bowel movements to outcomes in the eight-week Phase 3 ABTECT induction trials.

Oral sessions to watch

On 19 October, Professor Bruce Sands is scheduled to present efficacy and safety from the 44-week, randomised, double-blind, placebo-controlled ABTECT-Maintenance trial, whilst a preclinical talk addresses obefazimod, miR-124 expression, inflammation and fibrosis. A further oral session covers the three-year Phase 2 results by prior advanced therapy use. On 20 October, an oral presentation examines maintenance results according to response to prior advanced therapy.

The company states that presentations will be posted to its publications page after the congress.

ADS Mechanics and a 17 October Congress Start

For ADS holders, the instrument tracks one ordinary share, so clinical news affects it indirectly through the value of the underlying equity, with currency movements between the euro and the dollar an additional factor. The congress offers a chance to see subgroup and long-term data, though conference presentations do not replace regulatory review.

The next confirmed date is the congress, which begins on 17 October 2026.